Homebiotech etf

biotech etf

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

November 29, 2022

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

November 29, 2022

Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

November 29, 2022

Investors who lost Money with shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) should contact the Shareholders Foundation in connection with the Lawsuit against Ampio Pharmaceuticals, Inc.

Investors who lost Money with shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) should contact the Shareholders Foundation in connection with the Lawsuit against Ampio Pharmaceuticals, Inc.

November 29, 2022

Trevena Regains Compliance with Nasdaq Listing Requirements

Trevena Regains Compliance with Nasdaq Listing Requirements

November 29, 2022

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

November 29, 2022

Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

November 29, 2022

EIGR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 9, 2023 in the Class Action Filed on Behalf of Eiger BioPharmaceuticals, Inc. Shareholders

EIGR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 9, 2023 in the Class Action Filed on Behalf of Eiger BioPharmaceuticals, Inc. Shareholders

November 29, 2022

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

November 28, 2022

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals Announces Reverse Stock Split

November 28, 2022

« 1 … 24 25 26 27 28 … 557 »